

CONSOLIDATED INDEPENDENT AUDITORS REPORT

**TO THE MEMBER OF
CHANDAN HEALTHCARE LIMITED**

Report on the Audit of Consolidated Financial Statements as at 31st March, 2025.

We have audited the Consolidated financial statements of **CHANDAN HEALTHCARE LIMITED**, which comprise the balance sheet as at 31st March 2025, and the statement of Profit and Loss, and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information. Which we have signed under reference to this report.

In our opinion and to the best of our information and according to the explanations given to us, the a fore said Consolidated financial statements give the information required by the **Companies Act, 2013** in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with Companies (Accounting Standards) Rules, 2021 ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31st 2025, the Profit for the year ended on that date.

Basis for Opinion

We conducted our audit of Consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of financial statements under the provisions of the Companies Act, 2013 and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on consolidated financial Statements.



Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 with respect to the preparation of these Consolidated financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of



internal control.

- Obtain an understanding of Internal Control relevant to Audit in order to design Audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control system.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decision of the reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) Planning the Scope of our audit work and in evaluating the result of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Report on Other Legal and Regulatory Requirements

1. As required by the Companies(Auditor's Report)Order,2020, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:

- a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c. The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d. In our opinion, the aforesaid Consolidated financial statements comply with the Accounting Standards specified under Section133 of the Act, read with Rule 7 of the **Companies (Accounting Standards) Rules, 2021**.
- e. On the basis of the written representations received from the directors as on 31stMarch 2025, taken on record by the Board of Directors, none of the directors is disqualified as on 31st March2025, from being appointed as a director in terms of Section 164(2) of the Act.
- f. In our opinion, the provision of section 143(3)(i) with regard to the opinion on internal financial controls with reference to financial statements and the operating effectiveness of such controls is applicable to the company.

3. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the **Companies (Audit and Auditors) Rules, 2014**, in our opinion and to the best of our information and according to the explanations given to us:

- The Company does not have any pending litigations in financial statements, which would impact on its financial position.
- The Company does not have any long-term contracts, including derivative contracts for which there were any material foreseeable losses.
- There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



- (i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity (ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (ii) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity (ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (iii) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material misstatement.
- The company has not declared or paid any dividend during the year.
4. In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


Navodit Tyagi
Partner
Membership No.-533375
UDIN No:25533375BMOKNL8635
Place: Noida
Date: 27/05/2025



Annexure A to the Independent Auditor's report to the Shareholder


To the Independent Auditors' Report on the Consolidated Financial Statement of
CHANDAN HEALTHCARE LIMITED

In terms of the information and explanations sought by us and given by the company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

(xxi) In Respect of Qualification or Adverse remarks of Auditors on Group Companies:

There are no qualifications or adverse remarks by the respective auditors in the Companies (Auditors Report) Order (CARO) reports of the companies included in the consolidated financial statements. Accordingly, the requirement to report on clause 3(xxi) of the Order is not applicable to the Holding Company.

For MSNT & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.018542C/C400322


Navodit Tyagi
Partner
Membership No.-533375
UDIN No:25533375BMOKNL8635
Place: Noida
Date: 27/05/2025



Annexure B to the Independent Auditors' Report
Report on the Internal Financial Controls under Clause (i) of sub-section 3 of
Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of **CHANDAN HEALTHCARE LIMITED** as of 31st March 2025 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial



statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of the Management and directors of the Company; and
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.


Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For MSNT & ASSOCIATES LLP

Chartered Accountants

Firm Registration No. 018542C/C400322


Navodit Tyagi
Partner



Membership No.-533375
UDIN No:25533375BMOKNL8635
Place: Noida
Date: 27/05/2025



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement of Assets & Liabilities as at 31st March, 2025

Particulars	Note No.	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share capital	3	2,445.21	2,000.00
(b) Reserves and surplus	4	9,815.13	2,116.11
(c) Money received against share warrants	-	-	-
(2) Share application money pending allotment	-	-	-
(3) Minority interest	5	380.45	246.02
(4) Non-current liabilities			
(a) Long-term borrowings	6	2,214.46	1,217.56
(b) Deferred tax liabilities(net)	7	172.29	139.35
(c) Other long-term liabilities	8	2.45	0.45
(d) Long term provisions	9	343.69	305.75
(5) Current liabilities			
(a) Short-term borrowings	10	2,601.92	2,373.55
(b) Trade payables	11		
(i) Total outstanding dues of micro & small enterprises.		1,008.76	701.77
(ii) Total outstanding dues of creditors other than micro & small enterprises.		1,569.52	1,249.19
(c) Other current liabilities	12	438.78	1,422.77
(d) Short term provisions	13	69.04	34.68
TOTAL		21,061.70	11,807.20
II. ASSETS			
(1) Non- current assets			
(a) Property, plant & equipments & intangible assets	14		
(i) Property, plant & equipments		7,191.99	4,406.11
(ii) Intangible assets		443.28	443.28
(iii) Capital work in progress		410.12	-
(iv) Intangible assets under development		-	-
(b) Non-current investments	15	114.75	337.72
(c) Deferred tax assets(net)	-	-	-
(d) Long -term loans and advances	16	54.08	119.55
(e) Other non-current assets	17	1,816.52	367.47
(2) Current assets			
(a) Current investments	-	-	-
(b) Inventories	18	3,137.07	1,824.37
(c) Trade receivables	19	4,669.74	2,860.93
(d) Cash and bank balances	20	620.71	389.99
(e) Short-term loans and advances	21	960.03	821.54
(f) Other current assets	22	1,643.41	236.24
TOTAL		21,061.70	11,807.20

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered Accountants

Firm registration no. :- 018542C/C400322

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNL8635

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar Singh

Managing Director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025

Asmita Singh

Managing Director

Din. :- 01098055

Place :- Lucknow

Date :- 27th May 2025

Rajeev Nain

CFO & Company secretary

Place :- 27th May 2025

Date :- Lucknow

Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Audited Consolidated Statement of Profit and Loss for the year ended 31st March, 2025

Particulars	Note No.	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
I. Revenue from operations	23	23,012.08	17,659.01
II. Other income	24	205.14	122.18
III. Total revenue(I+II)		23,217.22	17,781.19
IV. Expenses:			
Cost of material consumed	25	1,545.88	1,107.69
Purchase of stock-in-trade	26	9,498.14	7,241.77
Change in inventories of finished goods,work-in-progress and stock-in-trade.	27	(282.32)	(264.47)
Employee benefits expense.	28	3,886.11	3,542.40
Finance Costs	29	457.53	275.23
Depreciation and amortisation expense	14	674.48	340.40
Other expenses	30	4,230.93	3,392.10
Total expenses (IV)		20,010.75	15,635.12
V. Profit/(loss) before exceptional & extraordinary items and tax (III-IV)		3,206.47	2,146.07
VI. Exceptional items		-	-
VII. Profit/(loss) before extraordinary items and tax (V-VI)		3,206.47	2,146.07
VIII. Extraordinary items		-	-
IX. Profit/(loss) before tax (VII- VIII)		3,206.47	2,146.07
X. Tax expense of continuing operation:-			
Current tax		830.58	510.56
Deferred tax		24.34	(0.07)
Tax expense(X)		854.92	510.49
XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)		2,351.55	1,635.58
XII. Profit/(loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)		-	-
XV. Share of (profit)/ loss transferred to minority interest		(134.43)	(7.85)
XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)		2,217.12	1,627.73
XVII. Earnings per equity share:			
(1) Basic	31	10.78	8.14
(2) Diluted		10.78	8.14

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered Accountants

Firm registration no. :- 018542C/C400322

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNL6635

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors
Chandan Healthcare Limited

Amar Singh

Managing Director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025

Asmita Singh

Managing Director

Din. :- 01098055

Place :- Lucknow

Date :- 27th May 2025

Rajeev Nain

CFO & Company secretary

Place :- 27th May 2025

Date :- Lucknow

Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise)

Audited Consolidated Statement of Cash Flow for the year ended 31st March, 2025

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
A. Cash flow arising from operating activities		
Profit / (Loss) before tax	3,206.47	2,146.07
Adjustments related to non-cash & non operating transactions:		
Non cash transactions		
Depreciation & amortisation of fixed assets	674.48	340.40
Bad Debts & Balances written off/written back	(124.78)	3.52
Re-measurement (gains) / loss on defined benefit plans	84.27	89.77
Provision for doubtful debts	15.35	5.24
Provision for obsolete inventories	26.72	6.26
Non operating transactions		
Interest on borrowing	441.79	260.72
Interest income	(72.98)	(24.50)
Dividend income	-	(75.98)
Operating profit/(loss) before working capital changes	4,251.32	2,751.48
Adjustment for change in working capital:		
(Increase) / Decrease in inventories	(1,339.42)	(843.51)
(Increase) / Decrease in trade receivables	(1,699.38)	(295.98)
(Increase) / Decrease in other current assets	(2,929.24)	(571.10)
(Decrease) / Increase in trade payables	543.05	(1,350.13)
(Decrease) / Increase in other current liabilities	(876.75)	911.49
Net cash (used in) / generated from operating activities	(2,050.42)	602.25
Income taxes refund / (paid), net	(854.92)	(490.54)
Net cash flow from operating activities(A)	(2,905.34)	111.71
B. Cash flow arising from investing activities		
Sale/(Purchase) of tangible and intangible assets	(3,870.48)	(1,954.19)
Sale/(Purchase) of non current & current investments	222.97	370.97
Interest income	72.98	24.50
Dividend income	-	75.98
Net cash flow from investing activities(B)	(3,574.53)	(1,482.73)
C. Cash Flow Arising From Financing Activities		
Proceeds from issuance of share capital	6,227.11	-
Proceeds from/(Payment of) long term & short term borrowings	1,225.27	2,065.77
Finance cost paid (including processing fees)	(441.79)	(260.72)
Dividend paid	(300.00)	(248.45)
Net cash flow from financing activities(C)	6,710.59	1,556.60
Net increase/decrease in cash or cash equivalents(A+B+C)	230.72	185.58
Cash and cash equivalents at the beginning of the period	389.99	204.41
Cash and cash equivalents at the end of the period	620.71	389.99

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered Accountants

Navodit Tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKNL8635

Place :- Noida

Date :- 27th May 2025



For & on behalf of the board of directors

Chandan Healthcare Limited

Amar Singh

Managing Director

Din. :- 01096328

Place :- Lucknow

Date :- 27th May 2025

Asmita Singh

Managing Director

Din. :- 01098055

Place :- Lucknow

Date :- 27th May 2025

Rajeev Nain

CFO & Company secretary

Place :- 27th May 2025

Date :- Lucknow

Chandan Healthcare Limited
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 1 : Corporate information

Chandan Healthcare Limited, established on September 3, 2003, specializes in operating state-of-the-art laboratories that offer comprehensive pathological investigations. Our services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, we provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. Committed to accuracy and reliability, Chandan Healthcare supports healthcare professionals and patients by delivering essential diagnostic services.



Note No. :- 2 : Summary of Significant accounting policies

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with the historical cost convention, accrual basis, and going concern assumption, as mandated by generally accepted accounting principles (GAAP) in India. GAAP encompasses the mandatory accounting standards specified under Section 133 of the Companies Act, 2013, in conjunction with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Act (to the extent notified).

Accounting policies have been applied consistently throughout, except where the initial adoption of a new accounting standard or a revision to an existing accounting standard necessitates a change in the previously applied accounting policy.

The financial statements are prepared in accordance with Schedule III of the Companies Act, 2013, which significantly influences their disclosure and presentation. Comparative figures for the previous year have been regrouped or reclassified, as necessary, to align with the current year's classification and disclosure requirements.

The standalone financial statements were approved by the Board of Directors and authorised for issue on May 27, 2025.

b) Use of Estimates

The preparation and presentation of financial statements necessitate the use of estimates and assumptions that impact the reported amounts of assets, liabilities, and contingent liabilities as of the financial statement date, as well as the reported revenues and expenses for the reporting period. Any variances between actual results and estimates are recognized in the period in which they become known or materialize.

Accounting estimates are subject to periodic revisions, and actual results may differ from these estimates. Adjustments to estimates are made when management becomes aware of changes in the circumstances affecting the estimates. Such changes are reflected in the financial statements for the period in which they occur, and their impact is disclosed in the notes to the financial statements if deemed material.

c) Functional and presentation currency

These standalone financial statements are presented in Indian Rupees (Rs.), which is also the Company's functional currency. All amounts have been rounded to the nearest lakhs, unless otherwise indicated.

d) Current and non-current classification:

The Company classifies an asset as current when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
- it expects to realise the asset within twelve months after the reporting period;
- it holds the asset primarily for the purpose of trading; or
- the asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non current.

A liability is classified as a current when

- it is expected to be settled in the Company's normal operating cycle;
- the liability is due to be settled within twelve months from the reporting period;
- it is held primarily for the purposes of being trading;
- it does not hold an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months.



e) Significant accounting policies

i.) Revenue recognition

Revenue from the **sale of goods** is recognized when ownership, along with all significant risks and rewards, has been transferred to the buyer, and when there is no significant uncertainty regarding the amount of consideration to be received from the sale.

Revenue from the **sale of services** is recognized using the **completed service contract method**, provided there is no significant uncertainty regarding the amount of consideration to be received for rendering the service.

Sales are accounted for net of amounts recovered towards gst and sales returns.

Sales returns are recorded upon the actual receipt of returned goods or the settlement of claims.

Revenue arising from the use by others of enterprise resources yielding interest and dividends should only be recognised when no significant uncertainty as to measurability or collectability exists. These revenues are recognised on the following bases:

Interest: On a time proportion basis taking into account the amount outstanding and the rate applicable.

Dividends: When the owner's right to receive payment is established.

ii.) Inventories

Inventories comprise of diagnostic kits, reagents, laboratory chemicals and consumables, these are measured at lower of cost and net realisable value. The cost of inventories is based on the **weighted average cost formula** and includes expenditure incurred in acquiring the inventories and other costs incurred in bringing them to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale. The comparison of cost and net realisable value is made on an item-by-item basis.

iii.) Property, plant & equipments

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefit associated with the item will flow to the Company and the cost of the item can be measured reliably. Items of property, plant and equipment (including capital-work-in progress) are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and any accumulated impairment losses. Freehold land is carried at historical cost less any accumulated impairment losses.

Cost of an item of property, plant and equipment comprises its purchase price, including non refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the items to its working conditions for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of asset.

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

iv.) Intangible assets

Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.



v.) Depreciation & Amortisation

Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values over their useful lives.

The Company has charged depreciation on property, plant & equipment (PPE) based on the Straight line Method (SLM) as per useful life specified in schedule II of the Companies Act, 2013.

Amortisation is calculated to write off the cost of intangible assets less their estimated residual values over their estimated useful lives using the straight line method (SLM) and is included in depreciation and amortisation expense in statement of profit and loss.

Depreciation and amortisation on additions and deletions are restricted to the period of use.

Residual value is considered to be 5% on all the assets.

Assets costing below Rs. 5,000 are depreciated using depreciation rate at 100%.

Depreciation and amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

vi.) Employee benefits

Short-term employee benefits

Short term employee benefits are measured on an undiscounted basis and expensed as the related service is provided. A short term liability is recognised if the Company has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

A defined contribution plan is a post-employment benefit plan where the company's legal or constructive obligation is limited to the amount that it contributes to a separate legal entity. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. The company makes specified monthly contributions towards government administered provident fund scheme and employees' state insurance ('ESI') scheme. Obligations for contributions to defined contribution plans are expensed as an employee benefits expense in statement of profit and loss in the period in which the related services are rendered by employees.

Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The company has a defined benefit plan namely gratuity for all its employees. Liability for defined benefit plan is provided on the basis of valuations, as at the balance sheet date, carried out by an independent actuary. The actuarial valuation method used by independent actuary for measuring the liability is the Projected Unit Credit Method. Actuarial gains and losses due to changes in actuarial assumptions and are recognised immediately in the profit and loss account as income or expense. Current and non current liabilities are recognised on the basis of actuarial report.

Termination benefits

Termination benefits are recognised as an expense as and when incurred.

vii.) Lease

Lease contracts entered by the company majorly pertains for buildings taken on operationg lease to conduct its business in the ordinary course. Leases where the lessor effectively retains substantially all the risks and benefits of the leased assets are classified as operating leases. Operating lease payments are recognized in the statement of profit and loss on a straight line basis over the lease term. Lease agreements are renewable for further period or periods on terms and condition as mutually agreed with the lessor. Variation or escalations clauses in lease rentals are made as per mutually agreed terms and conditions with the lessor.

viii.) Impairment of assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the statement of profit and loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is increased/ reversed where there has been change in the estimate of recoverable value. The recoverable value is the higher of the assets' net selling price and value in use. At each reporting date, the Company reviews the carrying amount of assets, to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.



ix.) Investments

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term Investments are stated at cost or fair value . Provision for diminution in the value of long term investments is made only if such a decline is other than temporary in the opinion of the management.

x.) Income-tax

Provision for income tax is made on the basis of taxable income for the year at current rates. Tax expense comprises of current tax and deferred tax at the applicable enacted or substantively enacted rates. Current tax represents the amount of income tax payable/ recoverable in respect of the taxable income/ loss for the reporting period. Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originate in one period and are capable of reversal in one or more subsequent periods.

The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that the assets will be realised in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is virtual certainty of realisation of assets.

Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and Loss as current tax. The company recognizes the MAT credit available as an asset only to the extent that there is convincing evidence that the company will pay the normal income tax during the specified period i.e., period for which MAT credit is allowed to be carried forward.

xi.) Provision, contingent liabilities and contingent assets

A **provision** is recognised when the company has a present obligation (legal or constructive) as a result of past event and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to its present value and are determined based on Management's estimate for the amount required to settle the obligation at the balance sheet date.

Contingent liability is a possible obligation arising from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or a present obligation that arises from past events but is not recognized because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

Contingent assets are neither recognised nor disclosed in the financial statements, since this may result in the recognition of income that may never be realised. However, when the realisation of income is virtually certain, then the related asset is not a contingent asset and is recognized.

Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

xii.) Earnings per share

Basic Earnings per share

Basic Earnings Per Share ('EPS') is calculated by dividing the profit attributable to the equity shareholders of the company by the weighted average number of equity shares outstanding during the year.

Diluted Earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

xiii.) Cash flow statement

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows are segregated into operating, investing and financing activities. The Company considers all highly liquid investments that are readily convertible to known amounts of cash to be cash equivalents.



xiv.) Cash and cash equivalents

Cash and cash equivalents in the balance sheet and cash flow statement consists of cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities less than three months which are readily convertible to known amounts of cash and which are subject to insignificant risk of changes in value.

xv.) Dividend

The company recognises a liability for any dividend declared but not distributed at the end of the reporting period, when the distribution is authorised and the distribution is no longer at the discretion of the company on or before the end of the reporting period.

xvi.) Related parties transactions

The company has a policy to recognize and identify related party transactions; disclosures of related party transactions have been made wherever applicable.

xvii.) Foreign Currency Transactions

Foreign exchange transactions are recorded at the rates prevailing on the date of transactions. Exchange rate differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year. Monetary assets and liabilities denominated in foreign currencies as at the balance sheet date are translated at the closing exchange rates on that date and the resultant exchange differences are recognized in the statement of profit and loss. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction. Non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rates that existed when the values were determined

xviii.) Borrowing Costs

Borrowing costs that are attributable to acquisition, construction or production of qualifying assets are capitalised as part of such assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred.

xix.) Events after reporting date

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.



Chandan Healthcare Limited
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 3 : Share capital

a. Information on authorised, issued, subscribed and paid-up shares

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Authorised		
Equity shares with voting rights (Current year : 25000000 equity shares of Rs.10/- each) (Previous year : 24000000 equity shares of Rs.10/- each)	2,500.00	2,400.00
Total...	2,500.00	2,400.00
Issued		
Equity shares with voting rights (Current year : 24452064 equity shares of Rs.10/- each) (Previous year : 20000000 equity shares of Rs.10/- each)	2,445.21	2,000.00
Total...	2,445.21	2,000.00
Subscribed and fully paid		
Equity shares with voting rights (Current year : 24452064 equity shares of Rs.10/- each) (Previous year : 20000000 equity shares of Rs.10/- each)	2,445.21	2,000.00
Total...	2,445.21	2,000.00



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ lakhs, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

a. The reconciliation of shares.

Particulars	Consolidated figures as at the end of 31st March, 2025			Consolidated figures as at the end of 31st March, 2024		
	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
<u>Equity shares with voting rights, subscribed and fully paid</u>						
Shares outstanding at the beginning of the year	20,000,000.00	10.00	2,000.00	20,000,000.00	10.00	2,000.00
Add: Fresh shares issued during the year	4,452,064.00	10.00	445.21	-	-	-
Add: Bonus shares issued during the year	-	-	-	-	-	-
Less: Shares forfeited/bought back during the year	-	-	-	-	-	-
Shares outstanding at the end of the year	24,452,064.00	10.00	2,445.21	20,000,000.00	10.00	2,000.00

b. Rights, preferences and restrictions of different classes of shares including restrictions on the distribution of dividends and the repayment of capital

Equity shares with voting rights, subscribed and fully paid	
As to dividend:	The shareholders are entitled to receive dividend in proportion to the amount paid up on the equity shares held by them.
As to repayment of capital:	In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.
As to voting:	The company has only one class of shares referred to as equity shares having a par value of Rs. 10/-. Each holder of the equity share is entitled to one vote per share.



U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ lakhs, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

c. Details of shareholders holding more than 5% shares of the Company

Name of shareholder	As at the end of 31st March, 2025			As at the end of 31st March, 2024		
	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)
Equity shares with voting rights, subscribed and fully paid						
Name of shareholder						
- Amar Anita Holdings (India) Private Limited	4,124,064.00	10	25.11%	5,843,000.00	10	56.99%
- Amar Singh	2,325,460.00	10	14.16%	2,319,860.00	10	22.63%
- Vinay Lamba	1,584,800.00	10	9.65%	1,584,800.00	10	15.46%
- Other shareholders*	16,423,340.00	10	100.00%	10,252,340.00	10	100.00%
Total...	24,452,064.00		100%	20,000,000.00		100%

*Other shareholders, each holding less than 5% of the total shares, are included here to ensure reconciliation of the total share count with the notes provided above.

d. Disclosure of shareholding of promoters:

As at 31st March, 2025

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	300,000	-	-	300,000	1.83%	-
-Amar Singh	2,319,860	5,600	-	2,325,460	14.16%	0.24%
-Amar Anita Holdings (India) Pvt Ltd	5,843,000	-	1,718,936	4,124,064	25.11%	-29.42%
-Asmita Singh	162,000	5,600	-	167,600	1.02%	3.46%
-Shaleen Solanki	900,000	-	-	900,000	5.48%	-
-Vijay Singh	899,400	-	-	899,400	5.48%	-
-Vinay Lamba	1,584,800	-	-	1,584,800	9.65%	-

As at 31st March, 2024

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
Name of promoter*						
-Alok Singh	300,000.00	-	-	300,000.00	2.93%	-
-Amar Singh	211,986.00	2,107,874.00	-	2,319,860.00	22.63%	994.35%
-Amar Anita Holdings (India) Pvt Ltd	5,843,000.00	-	-	5,843,000.00	56.99%	-
-Asmita Singh	162,000.00	-	-	162,000.00	1.58%	-
-Shaleen Solanki	900,000.00	-	-	900,000.00	8.78%	-
-Vijay Singh	899,400.00	-	-	899,400.00	8.77%	-
-Vinay Lamba	1,584,800.00	-	-	1,584,800.00	15.46%	-

*Individuals designated or to be designated by the company as promoters in its annual return.



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 4 : Reserves and surplus

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Securities premium account		
Securities premium account	5,782	-
Total A	5,782	-
Surplus/Retained earning		
Opening balance Reserves & Surplus	2,116.11	736.83
Less :- Dividend on equity shares	(300.00)	(248.45)
Add :- Profit/(Loss) for the period	2,217.12	1,627.73
Total B	4,033.23	2,116.11
Closing balance (A+B)	9,815.13	2,116.11



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 5 : Minority Interest


Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Opening Balance	246.02	238.17
Add: Minority Interest in current period Profit	134.87	7.85
Less: Minority Interest in current period loss	(0.44)	-
Total...	380.45	246.02

a. Disclosure of Subsidiaries' Share in Consolidated Net Assets and Profit and Loss

Particulars	Consolidated figures as at the end of 31st March, 2025		Consolidated figures as at the end of 31st March, 2024	
	Net Assets	Profit & Loss	Net Assets	Profit & Loss
Parent Company				
Chandan Healthcare Limited	12,260.34	2,351.55	4,116.11	1,635.58
Total Consolidated Net Assets & Net Profit	12,260.34	2,351.55	4,116.11	1,635.58
Parent Indian Subsidiaries				
Chandan Diagnostic Limited	48.37	(1.07)	49.43	1.66
Chandan Pharmacy Limited	804.44	290.43	514.01	15.80
Indira Diagnostic Centre & Blood Bank Limited	335.72	(15.52)	351.24	16.43
Total Subsidiaries Net Assets & Net Profit	1,188.52	273.84	914.68	33.90
Percentage of Subsidiaries share in consolidated net assets and profit				
Chandan Diagnostic Limited (% Holding 67.99%)	0.39%	-0.05%	1.20%	0.10%
Chandan Pharmacy Limited (% Holding 53.56%)	6.56%	12.35%	12.49%	0.97%
Indira Diagnostic Centre & Blood Bank Limited (% Holding 100%)	2.74%	-0.66%	8.53%	1.00%
Total percentage	9.69%	11.65%	22.22%	2.07%

b. Disclosure of minority Interest in all subsidiaries

Particulars	Consolidated figures as at the end of 31st March, 2025		Consolidated figures as at the end of 31st March, 2024	
	Share Capital	Reserve & Surplus	Share Capital	Reserve & Surplus
Parent Indian Subsidiaries				
Chandan Diagnostic Limited	31.01	350.07	381.08	215.20
Chandan Pharmacy Limited	15.00	(15.63)	(0.63)	(15.18)
Indira Diagnostic Centre & Blood Bank Limited	-	-	-	-
Total...	46.01	334.44	380.45	200.01
				246.02



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 6 : Long-term borrowings

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Term loans - From banks	2,214.46	1,217.56
Total...	2,214.46	1,217.56

a. Reconciliation of current and non current portion of long term liabilities

Particulars	Consolidated figures as at the end of 31st March, 2025			Consolidated figures as at the end of 31st March, 2024		
	Non current	Current	Total	Non current	Current	Total
Secured Term loans - From banks	2,214.46	734.29	2,948.75	1,217.56	585.60	1,803.16
Total...	2,214.46	734.29	2,948.75	1,217.56	585.60	1,803.16



Notes to consolidated financial statements for the Year ended 31st March, 2025

b. Other disclosure on term loan

Particulars	Consolidated figures as at the end of 31st March, 2025		Consolidated figures as at the end of 31st March, 2024		Details of repayment terms and maturity*		Nature of Security
	Amount	ROI	Amount	ROI	Particulars	Terms	
Secured							
Term Loan from Bank							
State Bank of India [41626319793]	-	-	35.42	7.95%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 83.00 2.56 30.00 05/06/2025	The loan is secured by the following: 1. Primary Security:- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. Collateral Security: A pari passu charge on immovable property, shared equally with other lenders who have similar security interests in the same property. This provides additional security for the lender, aligning their claim with those of other creditors. 3. Personal Guarantee: A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity. 4. Corporate Guarantee: A guarantee provided by AmarAnita Holdings (India) Pvt Ltd, ensuring that it will fulfill the loan obligations if the primary borrower fails to do so.
State Bank of India [41626315993]	-	-	208.67	7.95%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 308.00 7.21 50.00 17/10/2024	
State Bank of India [41626340656]	-	-	16.63	7.95%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 40.00 1.62 27.00 17/10/2024	
State Bank of India [41623614536]	-	-	42.48	8.30%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 46.00 1.19 49.00 17/10/2024	
Indusind Bank [73200008552]	40.82	8.75%	160.45	8.75%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	01/07/2022 340.24 10.74 36.00 07/08/2025	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
Yes Bank Limited [MEN00180126]	50.31	9.00%	68.90	9.00%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	21/07/2022 96.66 2.00 60.00 22/07/2027	
Yes Bank Limited [MEN001801285372]	10.86	7.95%	14.74	7.95%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	09/08/2022 20.20 0.42 60.00 22/08/2027	
HDFC Loan A/c No. [800450335]	146.96	9.50%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 178.13 6.50 31 07/04/2027	
HDFC Loan A/c No. [800450336]	2.45	9.50%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 9.57 1.24 8 07/05/2025	The loan is secured by the following: 1. Primary Security:- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. Personal Guarantee: A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity.
HDFC Loan A/c No. [800487587]	29.46	9.50%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 35.99 1.35 30.00 07/03/2027	
HDFC Loan A/c No. [99903818]	9.17	9.50%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 22.43 2.34 10 07/07/2025	
PNB LOAN A/c No. [241400CN00000057]	1,552.44	8.80%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	27/07/2024 1,650.00 19.64 84 30/04/2032	
PNB LOAN A/c No. [241400NG00259653]	15.84	8.80%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	04/10/2024 17.00 0.35 60.00 30/09/2030	Hypothecation of New Four Wheeler.
Punjab National Bank [241400CH00000028]	1,090.44	7.95%	1,255.88	7.95%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	31/03/2023 1,530.00 39.36 48.00 31/03/2028	The loan is secured by: 1. A first pari passu charge on the assets acquired with the proceeds of the loan. 2. The personal guarantee of all directors of the borrowing entity. 3. The corporate guarantee of AmarAnita Holdings (India) Pvt Ltd.
Total...	2948.75		1803.1647				
Less:- Current maturities of all long-term borrowings	(734.29)		(585.60)				
Total...	2,214.46		1,217.56				

* These are with respect to the balance sheet date.

The figures are presented in absolute terms and are not expressed in lakhs.



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 7 : Deferred tax liabilities(Net)

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Deferred tax liabilities(Net)	172.29	139.35
Total...	172.29	139.35

a. Disclosures regarding the components of net deferred tax liabilities

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Provision for gratuity	289.65	(79.97)
Provision for doubtful debts	(103.88)	(1.32)
Provision for obsolete inventories	(5.18)	(1.58)
W.D.V of property, plant & equipments & intangible assets	(8.30)	222.22
Total...	172.29	139.35



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 8 : Other long -term liabilities

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Other long-term liabilities		
- Trade deposits and security deposits which are not in the nature of borrowings	2.45	0.45
Total...	2.45	0.45



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 9 : Long term provisions

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Provision for gratuity	343.69	305.75
Total...	343.69	305.75

a. Details of employee benefits as required by the accounting standard 15 (revised) employee benefits are as under:
The company has classified the various benefits provided to employee's as under:-

I. Defined contribution plans

- a. Employee's provident fund.
b. Employee's state insurance.

During the year, the company has recognised the following amounts in the profit and loss account:

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Employers' contribution to provident fund*	95.66	75.92
Employers' contribution to employee's state insurance*	31.96	30.91
Total...	127.61	106.83

* Included in Contribution to Provident and Other Funds (Refer Note No. 28 Employee benefits expense)

II. Defined benefit plans

Gratuity disclosures as per accounting standard-15

(i) Table Showing Changes in Present Value of Obligations

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Present value of the obligation at the beginning of the period	340.43	248.78
Interest cost	24.68	18.66
Current service cost	70.47	59.91
Past Service Cost	-	-
Benefits paid (if any)	(11.97)	(8.42)
Actuarial (gain)/loss	(10.88)	21.50
Present value of the obligation at the end of the period	412.73	340.43

(ii) Key results (The amount to be recognized in the Balance Sheet):

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Present value of the obligation at the end of the period	412.73	340.43
Fair value of plan assets at end of period	-	-
Net liability/(asset) recognized in Balance Sheet and related analysis	412.73	340.43
Funded Status - Surplus/ (Deficit)	(412.73)	(340.43)

(iii) Expense recognized in the statement of Profit and Loss:

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Interest cost	24.68	18.66
Current service cost	70.47	59.91
Past Service Cost	-	-
Expected return on plan asset	-	-
Net actuarial (gain)/loss recognized in the period	(10.88)	21.50
Expenses to be recognized in P&L #	84.27	100.06

Included in Provision for gratuity (Refer Note No. 28 Employee benefits expense)

(iv) Current & Non Current Liability :

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Current Liability (Short Term)*	69.04	34.68
Non Current Liability (Long Term)	343.69	305.75
Total Liability	412.73	340.43

* Included in Provision for gratuity (Refer Note No. 12 Short term provisions)

(v) Reconciliation of liability in balance sheet

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Opening gross defined benefit liability/ (asset)	340.43	248.78
Expenses to be recognized in P&L	84.27	100.06
Benefits paid (if any)	(11.97)	(8.42)
Closing gross defined benefit liability/ (asset)	412.73	340.43



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 10 : Short-term borrowings

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Secured		
Loans repayable on demand		
- From banks-Overdraft(OD)	70.51	114.18
- From banks-Cash credit(CC)	1,097.13	1,673.77
Loans and advances from related parties	699.99	-
Current maturities of all long-term borrowings		
- From banks	734.29	585.60
	2,601.92	2,373.55

Particulars	Consolidated figures as at the end of 31st March, 2025		Consolidated figures as at the end of 31st March, 2024	
	Amount	Nature of security and other terms	Amount	Nature of security and other terms
Secured				
Loans repayable on demand				
- From banks-Overdraft(OD)				
- Icici Bank Limited	70.51	Sanctioned against FDs with ICIC Bank	114.18	Sanctioned against FDs with ICIC Bank
- Indian Overseas Bank	-	-	-	-
- From banks-Cash credit(CC)				
- State Bank of India (CC)	-	-	1,673.77	Hypothecation of stock and book debt
- HDFC (CC)	1,097.13	Hypothecation of stock and book debt		
Loans and advances from related parties	699.99	Unsecure loan, repayable on demand, From Directors and relative.	-	-



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 11 : Trade payables

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Trade payables		
- Total outstanding dues of micro enterprises and small enterprises	1,008.76	701.77
- Total outstanding dues of other than micro enterprises and small enterprises	1,569.52	1,249.19
	2,578.28	1,950.96

a. Trade payables ageing schedule

As at 31st March, 2025


Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	1,008.76	-	-	-	-	1,008.76
--Others	-	-	1,569.52	-	-	-	1,569.52
Disputed							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
Total...	-	1,008.76	1,569.52	-	-	-	2,578.28

As at 31st March, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
Not Disputed							
--MSME	-	701.77	-	-	-	-	701.77
--Others	-	-	1,249.19	-	-	-	1,249.19
Disputed							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
Total...	-	701.77	1,249.19	-	-	-	1,950.96

b. Disclosure as per MSMED Act, 2006

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Payable		
Principle overdue as per MSMED Act, 2006.	-	701.77
Principle not due as per MSMED Act, 2006.	1,008.76	-
Interest payable under section 16 of MSMED Act, 2006	-	-
- On principle paid beyond due date as per MSMED Act, 2006	-	-
- On principle payable beyond due date as per MSMED Act, 2006	-	-
- Carried forward from the last year	-	-
Other interest	-	-
Total...	1,008.76	701.77
Paid		
Principle paid beyond the due date as per MSMED Act, 2006	-	-
Interest paid under section 16 of MSMED Act, 2006	-	-
Total...	-	-



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 12 : Other current liabilities

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Advances from customers	1.05	852.25
TDS payable	45.90	59.77
GST payable	23.14	51.49
Salary, Bonus, Gratuity, Reimbursements etc. payable to staff	263.65	306.38
Contribution towards PF payable	15.92	15.03
Contribution towards ESI payable	3.42	2.99
Income tax payable OCL	32.39	134.86
Other payables (specify nature)	53.31	-
Total...	438.78	1,422.77



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 13 : Short term provisions

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Provision for employee benefits		
Provision for gratuity	69.04	34.68
	69.04	34.68



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 14 : Property, plant & equipments & intangible assets

Description	Gross block			Accumulated depreciation		Net block		
	Figures as at the beginning of 1st April, 2024	Additions during the year	Disposals during the year	consolidated figures as at the end of 31st March, 2025	Figures as at the beginning of 1st April, 2024	For the year	consolidated figures as at the end of 31st March, 2025	consolidated figures as at the end of 31st March, 2024
Tangible Assets								
Capital Work-In- Progress(CWIP)								
Buildings		410.12	-	410.12	-	-	410.12	-
Property, plant and equipment								
Computers	484.46	71.29	-	555.75	335.41	87.98	132.37	149.05
Electric Installation	110.49	1.73	-	112.22	80.14	0.89	31.20	30.35
Office Interior & Renovation	529.18	304.14	0.13	833.19	312.02	19.21	501.97	217.16
Buildings	322.51	-	-	322.51	85.54	14.71	222.26	236.97
Plant and equipment	5,964.24	2,799.98	-	8,764.22	2,459.05	361.19	5,943.98	3,505.19
Furniture and fixtures	159.17	51.84	-	211.01	109.10	45.62	56.29	50.07
Vehicles	104.71	62.03	-	166.74	79.35	6.68	80.71	25.37
Office equipment	309.40	169.48	-	478.87	117.45	138.21	223.22	191.95
Total Tangible Assets (A)	7,984.15	3,870.61	0.13	11,854.63	3,578.04	674.48	7,191.99	4,406.11
Intangible Assets								
Goodwill	443.28	-	-	443.28	-	-	443.28	443.28
Total Intangible Assets (B)	443.28	-	-	443.28	-	-	443.28	443.28
Total (A+B)	8,427.43	3,870.61	0.13	12,297.91	3,578.04	674.48	7,635.27	4,849.39
Previous Year...	6,493.24	1,954.19	20.01	8,427.43	3,237.64	340.40	4,849.39	3,255.60



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 15 : Non-current investments

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Investments in equity instruments	114.75	337.72
Total...	114.75	337.72

a. Disclosure on investment in equity instrument
As at 31st March, 2025

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Fully paid	1.59%	0.43	270	114.75	Valuers Value	Unquoted
Total...							114.75		

a. Disclosure on investment in equity instrument
As at 31st March, 2024

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	Associates	10	Fully paid	17.58%	1.25	270	337.72	Valuers Value	Unquoted
Total...							337.72		



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 16 : Long -term loans and advances

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Secured, considered good		
Capital Advances	-	41.90
Unsecured, considered good		
Income tax refund due	54.08	77.65
Total...	54.08	119.55



Chandan Healthcare Limited

U85110UP2003PLC193493

Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 17 : Other non-current assets

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Secured, considered good		
Security Deposits	199.77	100.68
Banks deposits with more than twelve months maturity	1,616.75	264.78
Unsecured, considered good		
Security Deposits	-	2.01
Total...	1,816.52	367.47



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 18 : Inventories

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Stock-in-trade	1,533.91	1,251.59
Stores,spares and consumables	1,636.14	579.04
Less: Provision for stock obsolescence	(32.98)	(6.26)
Total...	3,137.07	1,824.37



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 19 : Trade receivables


Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Unsecured, considered good	4,642.84	2,866.17
Trade receivables		
Doubtful	47.50	-
Trade receivables	(20.60)	(5.24)
Less: Provision for bad and doubtful trade receivables		
Total...	4,669.74	2,860.93

a. Trade receivable ageing schedule
As at 31st March, 2025

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	559.41	4,083.43	-	-	-	-	4,642.84
Trade Receivables – considered doubtful	-	-	26.90	-	-	-	-	26.90
Total...	-	559.41	4,110.33	-	-	-	-	4,669.74

As at 31st March, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	347.26	2,518.91	-	-	-	-	2,866.17
Trade Receivables – considered doubtful	-	-	(5.24)	-	-	-	-	(5.24)
Total...	-	347.26	2,513.67	-	-	-	-	2,860.93



Chandan Healthcare Limited

U85110UP2003PLC193493


Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 20 : Cash and bank balances

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Cash and cash equivalents		
Balances with banks	555.85	355.34
Cash on hand	64.86	34.65
Total...	620.71	389.99



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 21 : Short-term loans and advances

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Secured, considered good		
Loans and advances to related parties	-	10.00
Advance to supplier	72.02	21.57
Advance to employees	391.72	219.41
Other loans and advances (specify nature)	310.25	-
Unsecured, considered good		
Loans and advances to related parties	155.42	569.42
Advance to supplier	0.93	1.02
Advance to employees	1.11	-
Income tax refund due	28.58	0.12
Total...	960.03	821.54



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 22 : Other current assets

Particulars	Consolidated figures as at the end of 31st March, 2025	Consolidated figures as at the end of 31st March, 2024
Secured		
Input tax credit(ITC)-GST	14.30	49.66
Prepaid expenses	43.27	14.52
Bank deposits with more than three months maturity	1,583.65	134.66
Other	-	37.40
Unsecured		
Security Deposits	2.19	-
Total...	1,643.41	236.24



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 23 : Revenue from operations

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Sale of products	10,580	7,908
Sale of services	12,430	9,749
Other operating revenues	2	2
Sale of scrap	-	-
Less: Excise duty		
Total...	23,012	17,659



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 24 : Other income

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
<u>On current investments</u>		
Interest on fixed deposits	72.98	24.50
Dividends from other companies	-	75.98
<u>Other</u>		
Other Interest Income	-	5.93
Bad Debts Recovered & Reversal of Payable Write-Off(Net)	124.78	9.07
Other non-operating income	7.38	6.70
Total...	205.14	122.18



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 25 : Cost of material consumed

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Stores,spares and consumables	1,545.88	1,107.69
Total...	1,545.88	1,107.69

Consumption disclosed in Note is on the basis of derived figures rather than actual records of issue.



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 26 : Purchase of stock-in-trade

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Purchase of stores,spares and consumables	9,498.14	7,241.77
Total...	9,498.14	7,241.77



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 27 : Change in inventories of finished goods, work-in-progress and stock-in-trade.

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Opening stock:		
Stock-in-trade	1,251.59	987.12
	1,251.59	987.12
Closing stock:		
Stock-in-trade	1,533.91	1,251.59
	1,533.91	1,251.59
Total...	(282.32)	(264.47)



Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 28 : Employee benefits expense.

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Salaries and wages	3,661.18	3,331.05
Contribution to provident and other funds	127.61	106.83
Provision for gratuity	84.27	100.06
Staff welfare expense	13.05	4.46
Total...	3,886.11	3,542.40




Chandan Healthcare Limited
U85110UP2003PLC193493
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 29 : Finance costs

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Interest expense on borrowings	405.31	248.07
Other borrowing costs		
Loan processing charges	24.00	12.69
Bank charges	28.22	14.47
	457.53	275.23



Chandan Healthcare Limited
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 30 : Other expenses

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Repair & maintenance- Plant & equipments	125.35	93.26
Repair & maintenance-Building	40.39	34.61
Repair & maintenance- Other	99.54	42.10
Payment to auditors	20.80	10.66
Rent	636.55	471.42
Electricity expenses	264.07	174.90
Fuel expenses	59.75	41.18
Travelling and conveyance	1,034.41	771.79
Legal and professional fees (professional fees to doctor consultants and others) & other related expenditures	1,284.02	1,046.40
Books, periodicals & certifications	0.94	0.61
Commission expenses	-	0.17
Advertisement, publicity, marketing & business promotion expenses	93.79	114.23
Provision for doubtful debts	15.35	5.24
Provision for obsolete inventories	26.72	6.26
Communication expenses(Telephone & internet expenses)	51.76	37.83
Insurance	5.98	6.70
Postage & courier charges	4.16	3.35
Rates and taxes	26.78	0.54
Outsourced testing expenses	83.63	364.56
CSR Expenses	12.48	6.06
Discount to customers	4.76	2.43
Printing and Stationary Expenses	0.01	-
Other miscellaneous expenses	339.69	157.80
	4,230.93	3,392.10

a. Payment to the auditor

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
For statutory audit	9	7.73
For Other Services	5.5	1.50
Out of Pocket Audit Expenses	0	1.14
Total...	14.50	10.36

b. Prior period items

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Rent	3.69	11.66
Electricity expenses	2.28	11.00
Communication expenses(Telephone & internet expenses)	2.81	0.36
Rates and taxes	0.06	1.87
Other miscellaneous expenses	12.50	0.48
Total...	21.33	25.37



194IC	Payment under Specified Joint Development Agreement	-	10%	10%
-------	---	---	-----	-----

DS Rates for Other Payments

Section	Nature of Transaction	Threshold Limit (Rs)	TDS Rate (%)	
			Ind/HUF	Others
194LA	Compensation on transfer of certain immovable property other than agricultural land	Rs. 5 lakh	10%	10%
194LB	Income by way of interest from infrastructure debt fund (non-resident)	-	5%	5%
194LBA	Certain income from units of a business trust	-	10%	10%
194LBB	Income in respect of investment of investment fund	-	10% for residents, 30% for non-residents	10% for residents, 40% for non-residents
194LBC	Income in respect of investment in securitization trust	-	10% for residents, 40% for non-residents, 10% for individual & HUF	10% for residents, 40% for non-residents, 10% for individual & HUF
194M	Payment made for Contracts, Brokerage or Professional Fees etc. by Individual and HUF	Rs. 50 lakh	2%	2%
194N	Cash withdrawal in excess of 1 crore during the previous year from 1 or more account with a bank or co-operative society	1 Crore (Rs. 3 Crores, if withdrawal is by co-operative society)	2%	2%
		20 Lakh (if ITR not filed for previous 3 years)	2% (Rs. 20 Lakh – 1 Crore)	2% (Rs. 20 Lakh – 1 Crore)



			0% (Rs. 1 Crore and above)	0% (Rs. 1 Crore and above)
194O	TDS on e-commerce participants	Rs. 5 lakh	0.1%	0.1%
194P	TDS in case of Specified Senior Citizen (above 75 years) having Salary & Interest (ITR not required)	-	Slab Rates	NA
194Q	TDS on Purchase of Goods exceeding Rs. 50 Lakh	Rs. 50 lakh	0.1%	0.1%
194R	Benefits or perquisites of business or profession	Rs. 20,000	10%	10%
194S	Payment of consideration for transfer of virtual digital asset by persons other than specified person	Rs. 10,000	1%	1%
	Payment of consideration for transfer of virtual digital asset by specified person	Rs. 50,000	1%	1%
194T	Payments by Partnership Firms to Partners	Rs. 20,000	10%	10%

ote: TDS Rates when PAN is not available is flat 20% (if TDS applicable is lower than 20%).



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 31 : Earning per share

Basic/Diluted earnings per share are calculated by dividing the Net profit or Loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Numerator		
Earning available to equity share holders	2,217.12	1,627.73
Denominator		
Weighted average outstanding equity share capital	205.73	200.00
Earnings Per Rupees of Equity Share Capital (Basic/ Diluted)	10.78	8.14



Chandan Healthcare Limited

U85110UP2003PLC193493


Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 32 : Disclosure regarding Transactions with Related Parties in terms of Accounting Standard - 18


Name of the related party	Nature of the relationship 31st March 2025	Nature of the relationship 31st March 2024
A. Enterprises that directly or indirectly control/controlled by/under common control with, the reporting enterprise Chandan Diagnostic Limited- PAN: AABCC9315J Chandan Hospital Limited - PAN: AABCC9314K # Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L Chandan Pharmacy Limited - PAN: AAHCC1459M Chandan Institute Of Medical Sciences Limited - PAN: AAJCC1470E Candana Pharmaceuticals Private Limited - PAN: AAKCC1991P Amarantia Holdings (I) Private Limited - PAN: AAHCA1540R Chandan Singh Foundation - PAN: AAATC2479F Healthrely Private Limited- PAN: AAGCH9438N* Chandan Cancer Institute Limited-PAN: AALCC9159N* Chandan Super Speciality Hospital Limited- PAN: AALCC1234A*	Holding 67.99% of share capital Common director Holding 100% of share capital Holding 53.56% of share capital Holding 17.58% of share capital # Common director Common director Common director and trustee Common director Common director Common director	Holding 67.99% of share capital Common director Holding 100% of share capital Holding 53.56% of share capital Holding 17.58% of share capital Common director Common director Common director and trustee - - -
B. Individuals owning, directly or indirectly, an interest in the voting power of the reporting enterprise that gives them control or significant influence over the enterprise, and relatives of any such individual Dr Anar Singh - PAN: AQQPS5396H - DIN: 01096328 Asmita Singh - PAN: AWSPS3853M - DIN: 01098055 Virendra Singh - PAN: AFSPS0571B - DIN: 01098343 Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153 Vijay Singh - PAN: AILPS1503P - DIN: 02778087* Aasthi Singh - PAN: FRPPS0695A - DIN: 06973933* Anant Singh - PAN: AWSPS3852L - DIN: 00969384* Rishi Bhushan Kaila - PAN: ALVPK6157A - DIN: 08074018* Hari Shanker Dixit - PAN: AARPD6502Q - DIN: 02383137* Sandeep Kumar saraswat - PAN: APGPS5745F - DIN: 08354660* Rajeev Nain - PAN: AIVPN6380K Mohammad Mohsin Rizvi - PAN: AQXPR3625G Anita Singh - PAN: ARVPS1208G Vishal Lamba - PAN: ABUPL4208N Ajai Singh - PAN: AHNPS7885B Nisha Lamba - PAN: AATPL6545J Pragya Singh - PAN: DJVPS075J Shaivalini Singh - PAN: CURPS9141R Vikash Lamba - PAN: ACLPL2389Q Deepa Lamba - PAN: AAYPL1519B Anshu Lamba - PAN: ABQPL8605C	Managing director of company (MD) Director of company Director of company* Director of company Director of company* Relative of director Relative of director Director of company* Director of company* Director of company* Key managerial personnel (CFO & Company secretary) Relative of director Relative of director Relative of director Relative of director Relative of KMP Relative of director Relative of director Relative of director Relative of director	Managing director of company (MD) Director of company Director of company* Director of company Director of company Director of company Director of company Director of company Director of company Director of company Director of company Key managerial personnel (CFO & Company secretary) Relative of director Relative of director Relative of director Relative of director Relative of KMP Relative of director Relative of director Relative of director Relative of director




During the financial year, the company divested its investments in certain subsidiaries and associates. As a result of these transactions, these entities are no longer classified as subsidiaries or associates in the company's financial statements.
* During the financial year, the individual ceased to serve as a director

a. Details of transactions with related parties and amounts (receivable/payable) as at the beginning and end of the year:

Name of related party	Nature of Transaction	Standalone figures for the year ended 31st March, 2025	Standalone figures for the year ended 31st March, 2024
Aasti Singh	Opening Balance Payable(Receivable)	(0.00)	18.00
	Dividend for the Year	1.05	0.70
	Payment	(1.27)	(48.70)
	Receipt	-	-
Dr Amar Singh	Reimbursement	0.30	10.00
	Professional fee	-	20.00
	Closing Balance Payable(Receivable)	0.08	(0.00)
	Opening Balance Payable(Receivable)	17.59	11.52
	Dividend for the Year	34.80	21.20
	Professional fee	-	-
	Receipt	20.00	-
	Bonus for the Year	-	-
	Salary	180.00	14.00
	Payment	234.80	310.00
	Reimbursement	-	(339.88)
	Closing Balance Payable(Receivable)	487.18	0.75
Anita Singh	Opening Balance Payable(Receivable)	(0.00)	17.59
	Salary	-	(0.00)
	Reimbursement	-	35.26
	Receipt	-	-
	Commission	-	-
	Gratuity	-	-
	Payment	-	-
	Closing Balance Payable(Receivable)	(0.00)	(35.26)
Anant Singh	Opening Balance Payable(Receivable)	(0.00)	(0.00)
	Salary	-	-
	Dividend for the Year	1.58	1.05
	Advance	-	-
	Payment	(1.58)	(1.05)
	Closing Balance Payable(Receivable)	(0.00)	(0.00)
Rishi Bhushan Kalia	Opening Balance Payable(Receivable)	0.55	-
	Professional fee	32.04	43.85
	Reimbursement	9.02	3.66
	Dividend for the Year	2.33	-
	Payment	(46.04)	(46.97)
	Closing Balance Payable(Receivable)	(2.11)	0.55
Hari Shanker Dixit	Opening Balance Payable(Receivable)	-	-
	Reimbursement	0.16	-
	Dividend for the Year	6.00	4.00
	Payment	(6.16)	(4.00)
Asmita Singh	Opening Balance Payable(Receivable)	3.97	-
	Dividend for the Year	2.43	-
	Deposit	-	-
	Reimbursement	4.24	-
	Advance	-	-
	Bonus for the Year	-	-



Vinay Lamba	Salary Payment	84.00	72.03
	Closing Balance Payable(Receivable)	(63.29)	(122.78)
	Opening Balance Payable(Receivable)	31.35	3.97
	Payment	6.36	1.32
	Advance	(51.39)	(107.42)
Vijay Singh	Reimbursement	-	-
	Dividend for the Year	(0.64)	-
	Bonus for the Year	23.77	15.85
	Salary	21.90	10.00
	Closing Balance Payable(Receivable)	0.00	86.60
Sandeep Kumar saraswat	Opening Balance Payable(Receivable)	2.80	20.03
	Dividend for the Year	13.49	8.99
	Reimbursement	13.81	-
	Advance	-	1.70
	Gratuity	-	-
Virendra Singh Chaudhry	Payment	(76.68)	(31.67)
	Salary	45.00	3.75
	Closing Balance Payable(Receivable)	(1.57)	2.80
	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	4.62	3.08
Rajeev Nain	Payment	(4.62)	(3.08)
	Closing Balance Payable(Receivable)	0.00	8.08
	Opening Balance Payable(Receivable)	-	2.47
	Dividend for the Year	-	-
	Salary	-	-
Ajai Singh	Professional fee	-	-
	Gratuity	-	-
	Payment	-	-
	Closing Balance Payable(Receivable)	0.00	(10.54)
	Opening Balance Payable(Receivable)	2.22	0.66
Nisha Lamba	Dividend for the Year	1.91	0.24
	Reimbursement	6.03	(44.26)
	Gratuity	-	-
	Professional fee	-	-
	Payment	(55.79)	(3.78)
Pragya Singh	Salary	48.54	49.34
	Closing Balance Payable(Receivable)	2.90	2.22
	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	1.50	1.00
	Reimbursement	0.16	-
Shaivalini Singh	Payment	(1.66)	(1.00)
	Closing Balance Payable(Receivable)	-	-
	Opening Balance Payable(Receivable)	-	(0.88)
	Dividend for the Year	3.35	2.23
	Salary	-	-
Virendra Singh Chaudhry	Receipt	-	-
	Payment	(3.35)	0.88
	Closing Balance Payable(Receivable)	-	(2.23)
	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	-
Pragya Singh	Salary	-	14.19
	Closing Balance Payable(Receivable)	-	(14.19)
	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	0.35	0.23
	Payment	(0.35)	(0.23)
Sandeep Kumar saraswat	Closing Balance Payable(Receivable)	-	-
	Opening Balance Payable(Receivable)	-	-
	Dividend for the Year	-	-
	Salary	-	-
	Payment	-	-



Vikas Lamba	Opening Balance Payable(Receivable) Dividend for the Year Payment Advance Salary Gratuity Reimbursement Receipt Closing Balance Payable(Receivable)	0.00 7.50 (13.99) - - - 6.06 - (0.43)	78.10 5.00 (88.31) - - - 3.98 1.23 0.00
Vishal Lamba	Opening Balance Payable(Receivable) Dividend for the Year Advance Loan Salary Gratuity Payment Reimbursement Closing Balance Payable(Receivable)	(0.00) 2.32 - - - - - (19.91) 14.72 (2.88)	11.25 1.54 - - - - - 11.25 (25.04) 1.00 (0.00)
Anshu Lamba	Opening Balance Payable(Receivable) Dividend for the Year Salary Reimbursement Payment Closing Balance Payable(Receivable)	- 3.00 - - - (3.00)	- 2.00 11.66 (0.00) (13.66) -
Deepa Lamba	Opening Balance Payable(Receivable) Dividend for the Year Payment Closing Balance Payable(Receivable)	- 1.38 (1.38)	- 0.92 (0.92) -
Mohammad Mohsin Rizvi	Opening Balance Payable(Receivable) Salary Reimbursement Payment Closing Balance Payable(Receivable)	- - - - -	- 27.76 0.40 (28.16) -
Chandan Hospital Limited	Closing Balance Payable(Receivable) Opening Balance Payable(Receivable) Opening Balance Investment in equity share capital Receipt Dividend Income Sales Share sales Share purchase Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable)	849.58 - 1,849.80 - (1,032.94) - - (1,840.07) - (173.64)	197.86 (286.17) 2,757.18 (42.93) (311.69) 286.17 - (1,750.84) - 849.58
Chandan Institute of Medical Sciences Limited	Opening Balance Payable(Receivable) Share sales Share Purchase Receipt Payment Closing Balance Investment in equity share capital Closing Balance Payable(Receivable)	26.27 (245.97) 445.93 (199.97) 6.65 (32.93) - 0.00	158.83 (222.97) - (23.00) - (132.56) (245.97) 26.27
Chandan Pharmacy Limited	Opening Balance Payable(Receivable) Sales Purchase Receipt Dividend Income	2.92 (474.00) (57.46) 21.68 54.38 -	565.96 (474.00) (16.09) 20.23 - (23.35)



Chandan Singh Foundation	Share sales			
	Payment	(25.30)		(543.83)
	Closing Balance Investment in equity share capital	(474.00)		(474.00)
	Closing Balance Payable(Receivable)	(3.78)		2.92
	Opening Balance Investment in equity share capital			
Chandan Diagnostic Limited	Share sales	445.93		-
	Share Purchase	(150.00)		-
	CSR	12.48		6.06
	Payment	(12.48)		(6.06)
	Closing Balance Investment in equity share capital	295.93		-
Indra Diagnostic Centre & Blood Bank Limited	Closing Balance Payable(Receivable)			
	Opening Balance Payable(Receivable)	(65.85)		45.98
	Share sales			(65.85)
	Sales	0.32		-
	Receipt			-
Cendana Pharmaceuticals	Payment	(0.32)		29.00
	Closing Balance Investment in equity share capital	(65.85)		(74.98)
	Closing Balance Payable(Receivable)			(65.85)
	Opening Balance Payable(Receivable)	4.57		-
	Opening Balance Investment in equity share capital	(491.69)		348.70
Chandan Super Speciality Hospital Limited	Sales	(340.28)		(491.69)
	Share sales			-
	Receipt	680.00		162.37
	Payment			(506.50)
	Closing Balance Investment in equity share capital	(491.69)		(491.69)
Amaranita Holdings (I) Private Limited	Closing Balance Payable(Receivable)	344.30		4.57
	Opening Balance Payable(Receivable)	4.57		-
	Receipt	178.60		44.68
	Payment	(165.38)		(44.68)
	Cheque Issued But Not Cleared	(1.18)		0
Amaranita Holdings (I) Private Limited	Purchase	297.61		4.57
	Sales	(81.36)		-
	Closing Balance Payable(Receivable)	232.86		-
	Opening Balance Payable(Receivable)			4.57
	Opening Balance Investment in equity share capital			-
Amaranita Holdings (I) Private Limited	Receipt	97.69		-
	Payment	(1.78)		-
	Sales	(103.82)		-
	Closing Balance Payable(Receivable)	(7.91)		-
	Opening Balance Payable(Receivable)	0.20		-
Amaranita Holdings (I) Private Limited	Share sales	584.30		584.30
	Professional Fee	(584.30)		-
	Commission			21.00
	Dividend	87.65		-
	Receipt	5.58		58.43
Amaranita Holdings (I) Private Limited	Payment	(93.43)		25.2
	Closing Balance Investment in equity share capital	584.30		(104.43)
	Closing Balance Payable(Receivable)			584.30
				0.20
				-



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 33 : Analytical ratios

Particulars	Consolidated figures for the year ended 31st March, 2025		Consolidated figures for the year ended 31st March, 2024		% Variance	Reason for more than 25% variance
Current Ratio						
Total current assets	11,030.96	1.94	6,133.07	1.06	82.83%	As a result of the substantial increase in current assets for the year.
Total current liabilities	5,688.02		5,781.96			
Debt-to- Equity Ratio						
Total liabilities	4,816.38	0.39	3,591.11	0.87	-54.97%	As result of the substantial increase in shareholders equity because of IPO
Total shareholder's equity	12,260.34		4,116.11			
Debt service coverage ratio						
EBIT	3,635.78	1.20	2,406.83	0.91	31.28%	As a result of the substantial increase in profitability for the current year.
Current debt obligation	3,031.23		2,634.31			
Return on Equity (%)						
PAT	2,217.12	27.08%	1,627.73	47.60%	-43.12%	As result Significant decline despite higher PAT, mainly due to a substantial increase in equity base, diluting shareholder returns.
Average shareholder's equity	8,188.23		3,419.48			
Inventory turnover ratio (in days)						
365* Average inventory	912,624	39.66	514,239	29.12	36.19%	As a result of change in accounting policy, refer # in note no 18
Sales	23,012		17,659			
Trade receivables turnover ratio (in days)						
365* Average account receivables	1,370,394	73.21	917,999	66.91	9.41%	NA
Net credit sales	18,720		13,720			
Trade payables turnover ratio (in days)						
365* Average trade payable	826,586	48.63	1,028,981	76.19	-36.17%	As result, Credit period shortened significantly.
Net credit purchase	16,998		13,506			
Net profit ratio (%)						
PAT	2,217.12	9.63%	1,627.73	9.22%	4.52%	NA
Sales	23,012.08		17,659.00			
Return on Capital Employed (%)						
EBIT	3,636	29.34%	2,407	35.04%	-16.28%	NA
Average (Shareholder's equity + Current & Non current borrowings)	12,391.97		6,867.93			
Interest Coverage ratio						
EBIT	3,635.78	7.95	2,406.83	8.74	-9.13%	NA
Interest Expenses	457.53		275.23			
Operating profit Ratio						
(Revenue- COGS-Operating Exp)	3,206.47	0.14	2,146.07	0.12	14.66%	NA
Sales	23,012		17,659			
Net Worth Ratio						
Shareholder fund	12,260.34	0.58	4,116.11	0.35	66.98%	As a result of the substantial increase in shareholder's fund w.r.t total assets for the year.
Total Asstes	21,061.70		11,807.20			



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 34 : Contingent liabilities and commitments

Particulars	Consolidated figures for the year ended 31st March, 2025		Consolidated figures for the year ended 31st March, 2024	
	No of cases	Amount	No of cases	Amount
Claims against the company not acknowledged as debts				
1) District consumer disputes redressal forum	13.00	62.49	11.00	64.98
2) State consumer disputes redressal commission	1.00	-	2.00	1.98
3) Labour court	3.00	5.45	6.00	28.52
4) District and session court	23.00	82.38	9.00	29.52
Direct tax matters	1.00	137.75	1.00	137.75
Guarantees				
Chandan Hospital Limited.	10.00	1,223.67	10.00	1,223.67
Chandan Pharmacy Limited.	1.00	227.76	1.00	227.76
Total...	52.00	1,739.50	40.00	1,714.18



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 35 : Segment reporting

Primary segments - Business Segments

The company primarily operates state-of-the-art laboratories providing comprehensive pathological investigations and radiology services. Other activities conducted by the company are ancillary to its main business and do not significantly impact the financial statements. Consequently, in accordance with Accounting Standard 17 on Segment Reporting, the company has identified a single reportable business segment: "Diagnostics Services." As a result, segment information has not been disclosed.

Secondary segments - Geographical Segments

The company operates primarily in India and there is no other significant geographical segment.



Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 36 : CSR expenditure

Particulars	Consolidated figures for the year ended 31st March, 2025	Consolidated figures for the year ended 31st March, 2024
Gross amount required to be spent by the company during the year.	12.46	4.86
Gross amount spent by the company during the year.	12.48	6.06
Shortfall/(Excess)	(0.02)	(1.20)

a. Disclosure on nature of CSR activities undertaken by the companies

Particulars	Consolidated figures for the year ended 31st March, 2025			Consolidated figures for the year ended 31st March, 2024		
	Paid in cash	Paid via bank	Total	Paid in kind	Paid via bank	Total
Promoting education	-	12.48	12.48	-	6.06	6.06



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to consolidated financial statements for the Year ended 31st March, 2025

Note No. :- 37 : Other statutory information

In the opinion of the board of directors, the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet.

Balances with trade receivables / trade payables and loans & advances are subject to confirmation.

Previous year's figures have been regrouped /rearranged wherever necessary to make them comparable with current year's figures.

The company does not have any benami property, where any proceeding has been initiated or pending against the company for holding any benami property.

The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 during the financial year.

The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

The company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

The company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with the understanding (whether recorded in writing or otherwise) that the company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

The company does not have any transaction to report that is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

The company has not been declared as wilful defaulter by any bank or financial institution or other lender.

The company does not have any immovable property (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company.

The company confirms that the quarterly returns or statements of current assets, filed with banks or financial institutions in relation to borrowings secured by current assets, are in agreement with the books of accounts.

